Author + information
- Received September 3, 1991
- Revision received November 25, 1991
- Accepted December 9, 1991
- Published online May 1, 1992.
- Hua Kong Lu, MDa,
- Zaomin Wu, MDa,
- Patrick Pauwels, MD∗,
- Henri Roger Lijnen, PhDa and
- Désiré Collen, MD, PhD∗,a
- ↵∗Address for reprints: Désiré Collen, MD, PhD, Center for Thrombosis and Vascular Research, Campus Gasthuisberg-University of Leuven, Building Teaching and Research, Herestraat 49, B-3000 Leuven, Belgium.
The chimeric molecule K1K2Pu, comprising the two kringle domains (K1and K2) of tissue-type plasminogen activator (t-PA) and the COOH-terminal region with the serine protease domain (Pu) of urokinase-type plasminogen activator (u-PA), was previously shown to have a 5- to 10-fold reduced clearance rate with maintained specific thrombolytic activity, resulting in an increased thrombolytic potency in animal models of venous and arterial thrombosis.
To document the thrombolytic potential of K1K2Pu, the thrombolytic potency and fibrin specificity were studied in a combined platelet-rich arterial eversion graft thrombosis and venous whole blood clot model in heparinized dogs (100 U/kg bolus and 50 U/kg per h infusion). Dose-response effects of bolus injections of K1K2Pu(0.032 to 0.25 mg/kg) were compared with those of recombinant t-PA (rt-PA) and of recombinant single chain u-PA (rscu-PA) (0.25 to 1.0 mg/kg each) in groups of five or six dogs, each given hcparin with or without the thromboxane synthase inhibitor/prostaglandin endoperoxide receptor antagonist ridogrel. Heparin and ridogrel in the absence of a thrombolytic agent did not produce arterial reflow or venous clot lysis in five dogs. Addition of K1K2Pu, rt-PA or rscu-PA resulted in a dose-dependent induction of arterial reflow and of venous clot lysis in the absence of systemic fibrinolytic activation and fibrinogen breakdown.
Consistent arterial reflow required 0.063 mg/kg of K1K2Puand 0.5 mg/kg of rt-PA or of rscu-PA. The thrombolytic potency for venous clot lysis, expressed as percent lysis per mg compound administered per kg body weight, was (mean ± SEM) 750 ± 160 for K1K2Pu, 68 ± 17 for rscu-PA (p < 0.001 vs. K1K2Pu) and 110 ± 29 for rt-PA (p < 0.001 vs. K1K2Pu). The plasma clearance rates were significantly lower for K1K2Puthan for rscu-PA and rt-PA. In the absence of ridogrel, arterial reflow was significantly slower and was followed by cyclic reocclusion and reflow; however, venous clot lysis was unaffected. Template bleeding times were not significantly altered in the absence but were markedly prolonged in the presence of ridogrel.
These results confirm and establish that, when given as a bolus injection, K1K2Puhas an approximately 10-fold higher thrombolytic potency for arterial and venous thrombolysis than does rt-PA or rscu-PA. Thrombolysis with K1K2Puis obtained in the absence of systemic fibrinolytic activation and fibrinogen breakdown. These properties suggest that K1K2Puoffers potential for thrombolytic therapy by bolus administration in patients with thromboembolic disease.
☆ This study was supported by research grants from the Geconcerteerde Onderzocksacties and the Nationaal Fonds voor Wetenschappelijk Onderzoek, Belgium.
- Received September 3, 1991.
- Revision received November 25, 1991.
- Accepted December 9, 1991.